Explore Our Biomarker Menu


Met (pY1349)

Biological or Clinical Significance:

c-MET is a disulfide-linked α/β heterodimeric cell surface tyrosine kinase receptor. Hepatocyte growth factor (HGF; also known as scatter factor) is the only known c-MET ligand. Binding of HGF to c-MET triggers c-MET receptor activation via autophosphorylation of the cytoplasmic domain and recruitment of adaptor proteins that potentiates cell signaling. Aberrant HGF/c-MET signaling via ligand dependent (both paracrine and autocrine) and ligand independent mechanisms is well documented in several human cancers and multiple therapeutic agents targeting this pathway are in clinical development. c-MET phosphorylation has been reported in Non-Small Cell Lung (NSCLC) carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and other carcinomas. Like most receptor kinases, improved methods for reliable measurement of c-MET receptor activation are needed.



Met (pY1349)



Experienced Running





Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.